{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:28:48Z","timestamp":1789140528855,"version":"build-2803163510"},"reference-count":40,"publisher":"American Institute of Mathematical Sciences (AIMS)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.3934\/neuroscience.2021015","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T05:31:18Z","timestamp":1612848678000},"page":"284-294","source":"Crossref","is-referenced-by-count":8,"title":["From the lab to the people: major challenges in the biological treatment of Down syndrome"],"prefix":"10.3934","volume":"8","author":[{"given":"Jean A","family":"Rondal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"University of Li\u00e8ge, Belgium","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2321","reference":[{"key":"key-10.3934\/Neuroscience.2021015-1","doi-asserted-by":"crossref","unstructured":"Asim A, Kumar A, Muthuswamy S, et al. (2015) Down syndrome: an insight of the disease. J Biomed Sci<\/i> 22: 41-50.","DOI":"10.1186\/s12929-015-0138-y"},{"key":"key-10.3934\/Neuroscience.2021015-2","doi-asserted-by":"crossref","unstructured":"Lyle R, Bena F, Gagos S, et al. (2009) Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. Eur J Hum Genet<\/i> 17: 454-466.","DOI":"10.1038\/ejhg.2008.214"},{"key":"key-10.3934\/Neuroscience.2021015-3","unstructured":"Homfray T, Farndon P (2014) Fetal anomalies. The geneticist's approach. Twining's textbook of fetal abnormalities<\/i> London: Churchill Livingstone, 139-160."},{"key":"key-10.3934\/Neuroscience.2021015-4","doi-asserted-by":"crossref","unstructured":"Rondal JA (2020) Down syndrome: A curative prospect? AIMS Neurosci<\/i> 7: 168-193.","DOI":"10.3934\/Neuroscience.2020012"},{"key":"key-10.3934\/Neuroscience.2021015-5","unstructured":"Li LB, Chang KH, Wang PR, et al. (2012) Trisomy correction in Down syndrome induced pluripotent stem cells. Cell Stem Cell<\/i> 11: 615-619."},{"key":"key-10.3934\/Neuroscience.2021015-6","doi-asserted-by":"crossref","unstructured":"Takahashi K, Tanabe K, Ohnuki M, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell<\/i> 131: 861-872.","DOI":"10.1016\/j.cell.2007.11.019"},{"key":"key-10.3934\/Neuroscience.2021015-7","doi-asserted-by":"crossref","unstructured":"Jiang J, Jing Y, Cost G, et al. (2013) Translating dosage compensation to trisomy 21. Nature<\/i> 500: 296-300.","DOI":"10.1038\/nature12394"},{"key":"key-10.3934\/Neuroscience.2021015-8","doi-asserted-by":"crossref","unstructured":"Amano T, Jeffries E, Amano M, et al. (2015) Correction of Down syndrome and Edwards syndrome aneuploidies in human cell cultures. DNA Res<\/i> 22: 331-342.","DOI":"10.1093\/dnares\/dsv016"},{"key":"key-10.3934\/Neuroscience.2021015-9","doi-asserted-by":"crossref","unstructured":"Aziz NM, Guedj F, Pennings JLA, et al. (2018) Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1\/Yey mouse models of Down syndrome. Dis Mod Mech<\/i> 11: dmm031013.","DOI":"10.1242\/dmm.031013"},{"key":"key-10.3934\/Neuroscience.2021015-10","doi-asserted-by":"crossref","unstructured":"Yu T, Li Z, Jia Z, et al. (2010) A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum Mol Genet<\/i> 19: 2780-2791.","DOI":"10.1093\/hmg\/ddq179"},{"key":"key-10.3934\/Neuroscience.2021015-11","unstructured":"Czerminsky JT, Lawrence JB (2020) Silencing trisomy 21 with XIST<\/i> in neural stem cells promotes neuronal differentiation. Dev Cell<\/i> 52: 294-308."},{"key":"key-10.3934\/Neuroscience.2021015-12","unstructured":"Dumont M (2008) Qualit\u00e9 et s\u00e9lection des embryons (embryo quality and selection). J Gyn\u00e9col Obst\u00e9t Biol Reprod<\/i> 17: S9-S13."},{"key":"key-10.3934\/Neuroscience.2021015-13","doi-asserted-by":"crossref","unstructured":"Braude P, Bolton V, Moore S (1988) Human gene expression first occurs between the four- and eight-cell stages of preimplantation development. Nature<\/i> 332: 459-461.","DOI":"10.1038\/332459a0"},{"key":"key-10.3934\/Neuroscience.2021015-14","doi-asserted-by":"crossref","unstructured":"Cimadomo D, Capalbo A, Ubaldi FM, et al. (2016) The impact of biopsy on human embryo developmental potential during preimplantation genetic diagnosis. Biomed Res Int<\/i> 2016: 7193075.","DOI":"10.1155\/2016\/7193075"},{"key":"key-10.3934\/Neuroscience.2021015-15","doi-asserted-by":"crossref","unstructured":"Ait Yahya-Graison E, Aubert J, Dauphinot L, et al. (2007) Classification of human chromosome21 gene-expression variations in Down syndrome: Impact on disease phenotypes. Am J Hum Genet<\/i> 81: 475-491.","DOI":"10.1086\/520000"},{"key":"key-10.3934\/Neuroscience.2021015-16","doi-asserted-by":"crossref","unstructured":"Thomazeau A, Lasalle O, Lafrati J, et al. (2014) Prefrontal deficits in a murine model overexpressing the Down syndrome candidate gene dyrk1a. J Neurosci<\/i> 34: 1138-1147.","DOI":"10.1523\/JNEUROSCI.2852-13.2014"},{"key":"key-10.3934\/Neuroscience.2021015-17","doi-asserted-by":"crossref","unstructured":"Chakrabarti L, Best TK, Cramer NP, et al. (2010) Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nat Neurosci<\/i> 13: 927-934.","DOI":"10.1038\/nn.2600"},{"key":"key-10.3934\/Neuroscience.2021015-18","doi-asserted-by":"crossref","unstructured":"Manley W, Anderson S (2019) Dosage counts: Correcting trisomy-21-related phenotypes in human organoids and xenografts. Cell Stem Cell<\/i> 24: 835-836.","DOI":"10.1016\/j.stem.2019.05.009"},{"key":"key-10.3934\/Neuroscience.2021015-19","unstructured":"Ishihara K, Shimizu R, Takata K, et al. (2019) Perturbation of the immune cells and prenatal neurogenesis by the triplication of the Erg-gene in mouse models of Down syndrome. Brain Pathol<\/i> 30: 75-91."},{"key":"key-10.3934\/Neuroscience.2021015-20","doi-asserted-by":"crossref","unstructured":"Liu ET, Bolcun-Filas E, Grass D, et al. (2017) Of mice and CRISPR: The post-CRISPR future of the mouse as a model system for the human condition. EMBO Rep<\/i> 18: 187-193.","DOI":"10.15252\/embr.201643717"},{"key":"key-10.3934\/Neuroscience.2021015-21","doi-asserted-by":"crossref","unstructured":"Fillat C, Bofill-De Ros X, Santos M, et al. (2014) Identification de genes clave implicados en el sindrome de Down mediante terapia genetica (Identification of key genes implicated in Down syndrome through genetic therapy). Rev Med Int Sindrome Down<\/i> 18: 21-28.","DOI":"10.1016\/S2171-9748(14)70049-2"},{"key":"key-10.3934\/Neuroscience.2021015-22","doi-asserted-by":"crossref","unstructured":"Guedj F, S\u00e9bri\u00e9 C, Rivals I, et al. (2009) Green tea polyphenols rescue brain defects induced by overexpression of DYRK1A. PLoS One<\/i> 4: e4606.","DOI":"10.1371\/journal.pone.0004606"},{"key":"key-10.3934\/Neuroscience.2021015-23","doi-asserted-by":"crossref","unstructured":"Stagni F, Giacomini A, Emili M, et al. (2016) Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome. Neuroscience<\/i> 333: 277-301.","DOI":"10.1016\/j.neuroscience.2016.07.031"},{"key":"key-10.3934\/Neuroscience.2021015-24","doi-asserted-by":"crossref","unstructured":"Stagni F, Giacomini A, Emili M, et al. (2017) Epigallocatechin gallate: A useful therapy for cognitive disability in Down syndrome? Neurogen<\/i> 4: e1270383.","DOI":"10.1080\/23262133.2016.1270383"},{"key":"key-10.3934\/Neuroscience.2021015-25","doi-asserted-by":"crossref","unstructured":"De la Torre R, De Sola S, Pons M, et al. (2014) Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. Mol Nut Food Res<\/i> 58: 278-288.","DOI":"10.1002\/mnfr.201300325"},{"key":"key-10.3934\/Neuroscience.2021015-26","doi-asserted-by":"crossref","unstructured":"De la Torre R, De Sola S, Hernandez G, et al. (2016) Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): A double-blind, randomized, placebo-controlled, phase 2 trial. Lancet Neurol<\/i> 15: 801-810.","DOI":"10.1016\/S1474-4422(16)30034-5"},{"key":"key-10.3934\/Neuroscience.2021015-27","unstructured":"Isbrucker RA, Edwards JA, Wolz E, et al. (2006) Safety studies on epigallocatechin gallate (EGCG) preparations. Part 3: teratogenicity and reproductive toxicity studies in rats. Food Chem Toxicol<\/i> 44: 651-661."},{"key":"key-10.3934\/Neuroscience.2021015-28","doi-asserted-by":"crossref","unstructured":"Doran E, Keator D, Head E, et al. (2017) Down syndrome, partial trisomy, and absence of Alzheimer's disease: The role of APP. J Alzheim Dis<\/i> 56: 459-470.","DOI":"10.3233\/JAD-160836"},{"key":"key-10.3934\/Neuroscience.2021015-29","doi-asserted-by":"crossref","unstructured":"Rafii MS, Donohue MC, Matthews DC, et al. (2019) Plasma neurofilament light and Alzheimer's disease biomarkers in Down syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). J Alzheim Dis<\/i> 70: 131-138.","DOI":"10.3233\/JAD-190322"},{"key":"key-10.3934\/Neuroscience.2021015-30","unstructured":"Snow AD, Mar H, Nochlin D, et al. (1990) Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome. Am J Pathol<\/i> 137: 1253-1270."},{"key":"key-10.3934\/Neuroscience.2021015-31","unstructured":"Belichenko P, Madani R, Rey-Bellet L, et al. (2016) An anti-beta-amyloid vaccine for treating cognitive deficits in a mouse model of Down syndrome. PLoS One<\/i> 11: e152451."},{"key":"key-10.3934\/Neuroscience.2021015-32","unstructured":"Guidi S, Stagni F, Bartesaghi R (2017) Targetting APP\/AICD in Down syndrome. Oncotarget<\/i> 8: 50333-50334."},{"key":"key-10.3934\/Neuroscience.2021015-33","unstructured":"Kimura R, Kamino K, Yamamoto M, et al. (2006) The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet<\/i> 16: 15-23."},{"key":"key-10.3934\/Neuroscience.2021015-34","doi-asserted-by":"crossref","unstructured":"Ryoo SR, Jeong HK, Radnaabazar C, et al. (2007) DYRK1A-mediated hyperphosphorylation of Tau: A functional link between Down syndrome and Alzheimer disease. J Biol Chem<\/i> 282: 34850-34857.","DOI":"10.1074\/jbc.M707358200"},{"key":"key-10.3934\/Neuroscience.2021015-35","doi-asserted-by":"crossref","unstructured":"Garcia-Cerro S, Rueda N, Vidal V, et al. (2017) Normalizing the gene dosage of DYRK1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes. Neurobiol Dis<\/i> 106: 76-88.","DOI":"10.1016\/j.nbd.2017.06.010"},{"key":"key-10.3934\/Neuroscience.2021015-36","doi-asserted-by":"crossref","unstructured":"Kawakubo T, Mori R, Shirotani N, et al. (2017) Neprilysin is suppressed by dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) in Down syndrome derived fibroblasts. Biol Pharm Bull<\/i> 40: 327-333.","DOI":"10.1248\/bpb.b16-00825"},{"key":"key-10.3934\/Neuroscience.2021015-37","doi-asserted-by":"crossref","unstructured":"Inglis A, Lohn Z, Austin JC, et al. (2014) A \u201ccure\u201d for Down syndrome: what do parents want? Clin Genet<\/i> 86: 310-317.","DOI":"10.1111\/cge.12364"},{"key":"key-10.3934\/Neuroscience.2021015-38","doi-asserted-by":"crossref","unstructured":"Long R, Drawbaugh ML, Davis CM, et al. (2019) Usage and attitudes about green tea extract and epigallocathechin-3-gallate (EGCG) as a therapy in individuals with Down syndrome. Complement Ther Med<\/i> 45: 234-241.","DOI":"10.1016\/j.ctim.2019.07.002"},{"key":"key-10.3934\/Neuroscience.2021015-39","doi-asserted-by":"crossref","unstructured":"Riggan KA, Niquist C, Michie M, et al. (2020) Evaluating the risks and benefits of genetic and pharmacologic interventions for Down Syndrome: Views of parents. Am J Intellect Dev Disabil<\/i> 125: 1-13.","DOI":"10.1352\/1944-7558-125.1.1"},{"key":"key-10.3934\/Neuroscience.2021015-40","unstructured":"Carlson L (2013) Research ethics and intellectual disability: Broadening the debates. Yale J Biol Med<\/i> 86: 303-314."}],"container-title":["AIMS Neuroscience"],"original-title":[],"link":[{"URL":"http:\/\/www.aimspress.com\/article\/doi\/10.3934\/Neuroscience.2021015?viewType=html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T05:31:55Z","timestamp":1612848715000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.aimspress.com\/article\/doi\/10.3934\/Neuroscience.2021015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.3934\/neuroscience.2021015","relation":{},"ISSN":["2373-7972"],"issn-type":[{"value":"2373-7972","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}